Executive Summary: Pharmacy Programs: Manufacturer Assistance, Discount Cards, 340B Access, and Every Dollar Left on the Table
LFP-10.06 — The Cost Management Frontier#
The standard pharmacy transaction in a small group level funded plan passes through the PBM-mediated network and misses billions of dollars in manufacturer assistance, discount programs, and 340B pricing that flow around that network. A TPA that builds systematic pharmacy cost recovery captures value that most plans leave entirely on the table.
Manufacturer patient assistance programs provide free or reduced-cost medications to patients who meet income and insurance criteria. The scale is substantial: AbbVie’s myAbbVie Assist program alone served more than 235,000 patients in 2024. Most programs require US residency, household income at or below 300 to 400 percent of the Federal Poverty Level, and limited coverage for the specific medication. For 2024, 400 percent of FPL for a household of four was approximately $120,000, extending eligibility well into the middle class. A member on Humira at a list price exceeding $80,000 per year who qualifies receives the medication at no cost. The NeedyMeds clearinghouse lists more than 400 such programs. The infrastructure for identifying them exists; what small plans lack is the systematic process for enrolling eligible members.
Copay assistance cards reduce member out-of-pocket costs for virtually every branded specialty medication. The plan-level interaction has become contested. Copay accumulator programs prevent manufacturer assistance from counting toward the member’s deductible or out-of-pocket maximum, shifting the full cost-sharing burden to the member once manufacturer assistance is exhausted. As of late 2025, 25 states, the District of Columbia, and Puerto Rico have enacted legislation restricting accumulators for state-regulated plans, covering approximately 17 percent of the total commercial market. Self-funded ERISA plans currently retain more flexibility under ERISA preemption, though litigation over state accumulator bans continues. Copay maximizer programs take the opposite approach, structuring copays to extract the maximum available manufacturer assistance. The choice between accumulator and maximizer designs reflects the plan sponsor’s philosophy about cost-sharing and member relations.
Pharmacy discount programs like GoodRx operate outside the PBM network. For many generic medications, cash pricing through these programs beats PBM-negotiated rates. 340B drug pricing, which offers discounts of 25 to 50 percent for covered entities, is accessible to small employer plan members indirectly when prescriptions are filled through federally qualified health centers, critical access hospitals, or their contract pharmacies.
Individual small employers cannot capture any of this systematically. A TPA managing 50 small group plans with 1,000 total members can build the infrastructure once and deploy it across the book. If that infrastructure costs $50,000 to build and $25,000 per year to operate, and recovers an average of $15,000 per plan, the 10:1 return justifies the investment. For a representative 25-person plan, PAP enrollment for two specialty drug members combined with optimized copay assistance and discount capture can recover $57,000 against a $375,000 expected claims fund, or 15 percent of total expected claims.